New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia

Haematologica

Volumn 82, Issue 4, 1997, Pages 478-495

  Carella, Angelo M ^a   Frassoni, Francesco ^a   Melo, Junia ^b   Sawyers, Charles ^c   Eaves, Connie ^d   Eaves, Allan ^d   Apperley, Jane ^b   Tura, Sante ^e   Hehlmann, Rudiger ^f   Reiffers, Josy ^g   Lerma, Enrica ^a   Goldman, John ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Istituto di Ematologia L e A Seragnoli   (Italy)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Chemotherapy; Chronic myelogenous leukemia; Interferon; Oncogenes; Stem cells; Transplantation

Indexed keywords

ANALYTIC METHOD; CHRONIC MYELOID LEUKEMIA; HUMAN; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; ONCOGENE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

ANIMALS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0031440310     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Santucci MA, Saglio G, Tura S. Pathogenesis and progression og chronic myeloid leukemia. Haematologica 1996; 81: 62-76.
2. Wiedemann LM, Karhi KK, Shivji M, et al. The correlation of break-point cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases Blood 1988; 71:349-355.
3. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the Ras protooncogenes in chronic myelogenous leukemia:a high frequency of Ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74:2629-33.
4. Selleri L, Emilia G, Luppi M, et al. Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia negative and "bcr negative". Hematol Pathol 1990; 4:67-77.
5. Melo JV, Goldman JM. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. Leukemia 1992; 6:786-90.
6. Melo JV, Gordon DE, Cross NC, et al. The BCR-ABL fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81:158-65.
7. Melo JV, Hochhaus A, Yan XH, et al. Lack of correlation between ABL-BCR expression and response of interferon-alpha in chronic myeloid leukaemis. Br J Haematol 1996; 92:684-6.
8. Inokuchi K, Inoue T, Tojo A, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78:3125-7.
9. Arden JC, Speak J, Hyde K, et al. Molecular analysis in chronic granulocytic leukaemia:location of breakpoints within M-bcr and relationship with presentation platelet counts. Clin Lab Haematol 1993; 15:253-8.
10. Inokuchi K, Futaki M, Yamada T, et al. The relationship between the site of breakpoints within the bcr gene and thrombopoiesis of Philadelphia-positive chronic myelocytic leukemia. Leuk Res 1991; 15:1067-73.
11. Opalka B, Wandl UB, Stutenkemper R, et al. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood 1992; 80:1854-5.
12. Martiat P, Ifrah N, Rassool F, et al. Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia 1989; 3:563-5.
13. Cervantes F, Urbano Ispizua A, Villamor N, et al. Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis: report of two cases with molecular studies. Leukemia 1993; 7:327-30.
14. Shepherd P, Suffolk R, Halsey J, et al. Analysis of molecular break point and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89:546-54.
15. Chissoe SL, Bodenteich A, Wang YF et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27:67-82.
16. Melo JV, Myint H, Galton DAG, et al. P190 BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8:208-11.
17. Pane F, Frigeri F, Sindona M, et al. Neutrophil-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR-ABL with C3/A2 junction). Blood 1996; 88:2410-4.
18. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76:1819-24.
19. Wada H, Mizutani S, Nishimura J, et al. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR-ABL fusion protein. Cancer Res 1995; 55:3192-6.
20. Yamagata T, Mitani K, Kanda Y, et al. Elevated platelet count features the variant type of BCR-ABL junction in chronic myelogenous leukaemia. Br J Haematol 1996; 94:370-2.
21. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial]. Blood 1996; 88:2375-84.
22. Marshall CJ. Specificity of receptro tyrosine kinase signaling:transient vs sustained extracellular signal-regulated kinase activation. Cell 1995; 80:179-185.
23. Medema RH, Bos JL The role of p21 ras in receptor tyrosine kinase signaling. Crit Rev Oncogen 1993; 4:615-61.
24. Mandanas RA, Leibowitz DS, Gharenbaghi K, et al. Roel of p21 Ras in p210 bcr-abl transformation of murine myeloid cells. Blood 1993; 82:1838-47.
25. Skorski T, Kanakaraj P, Ku DH, et al. Negative regulation of p120GAP GTPase promoting activity by p210 bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 1994; 179:11855-65.
26. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181:307-13.
27. Cortez D, Stoica G, Pierce JH, et al. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996; 13:2589-94.
28. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75:175-85.
29. Senechal K, Halpern J, Sawyers CL The CRKL adaptor protein transforms fibroblasts and functions in transformation by the Bcr-Abl oncogene. J Biol Chem 1996; 271:23255-61.
30. Gishizky ML, Cortez D, Pendergast AM:Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 1995; 92:10889-93.
31. Nichols GL, Raines MA, Vera JC, et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84:2912-8.
32. Salgia R, Uemura N, Okuda K, et al. CRKL links p210 BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995; 270:29145-50.
33. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80:199-211.
34. Davis RJ. MAPKs:new JNK expands the group. Trends Biochem Sci 1994; 19:470-3.
35. Marshall Ms. Ras target proteins in eukaryotic cells. Faseb J 1995; 9:1311-8.
36. Seger R, Krebs EG. The MAPK signaling cascade. Faseb J 1995; 9:726-35.
37. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995; 20:117-22.
38. Waskiewicz AJ, Cooper JA:Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 1995; 7:798-805.
39. Raitano AB, Halpern JR, Hambuch TM, et al. The Bcr-Abl leukemia oncogene activates Jun Kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995; 92:11746-50.
40. Sanchez I, Hughes RT, Mayer BJ, et al. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994; 372:794-8.
41. Dickens M, Rogers J, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science submitted, 1997.
42. Skorski T, Nieborowska-Skorska M, Szczylik C, et al. C-RAF-1 serine/theonine kinase is required in BCR/ABL dependent and normal hematopoiesis. Cancer Res 1995; 55:2275-8.
43. Okuda K, Matulonis U, Salgia R, et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994; 22:1111-7.
44. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequence of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13:5887-95.
45. Wang HG, Rapp UR, Reed JC. Bcr-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87:629-38.
46. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87:619-28.
47. Tauchi T, Boswell HS, Leibowitz D, et al. Coupling between p210 bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 1994; 179:167-175.
48. ten Hoeve J, Kaartinen V, Fioretos T, et al. Cellular interactions of CRKL, an SH2-SH3 adaptor protein. Cancer Res 1994; 54:2563-7.
49. Pelicci G, Lanfrancone L, Salcini AE, et al. Constitutive phosphorylation of the Shc proteins in human tumors. Oncogene 1995; 11:899-907.
50. Druker B, Okuda K, Matulonis U, et al. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 1992; 79:2215-20.
51. Gotoh A, Miyazawa K, Ohyashiki K, et al. Potential molecular implicated in downstream signaling pathways of p185 BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-γ 1, and phosphatidylinositol 3′-kinase. Leukemia 1994; 8:115-20.
52. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 1994; 13:764-73.
53. Carpino N, Wisniewski D, Strife A, et al. p62dok: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997; 88:197-204.
54. Yamanashi Y, Baltimore D. Identification of the Abl and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997; 88:205-11.
55. Tauchi T, Feng GS, Shen R, et al. SH2-containing phosphotyrosine phosphatase Syp is a target of p210 bcr-abl tyrosine kinase. J Biol Chem 1994; 269:15381-7.
56. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86:726-36.
57. Matsuguchi T, Inhorn RC, Carlesso N, et al. Tyrosine phosphorylation of p95 Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210 BCR/ABL Embo J 1995; 14:257-65.
58. Ernst TJ, Slattery KE, Griffin JD. p210 BCR/ABL and p160v-ABL induce an increase in the tyrosine phosphorylation of p93cFes. J Biol Chem 1994; 269:5764-9.
59. Gotoh A, Miyazawa K, Ohyashiki K, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR/ABL oncoprotein. Exp Hematol 1995; 23:1153-9.
60. Shuai K, Halpern J, ten Hoeve J, et al. Constitutive activation of STAT5 by the BCR/ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13:247-54.
61. Carlesso N, Frank DA, Griffin JD:Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) protein in hematopoietic cell lines transformed by BCR/ABL. J Exp Med 1996; 183:811-20.
62. McWhirter JR, Wang JYJ. An actin-binding function contributes to transformation by the BCR/ABL oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993; 12:1533-46.
63. Salgia R, Li JL, Lo SH, et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by p210 BCR/ABL. J Biol Chem 1995; 270:5039-47.
64. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210 BCR/ABL. Oncogene 1995; 11:1149-55.
65. Liu J, Campbell M, Guo JQ, et al. BCR/ABL tyrosine kinase is autophospharylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene 1993; 8:101-9.
66. Lu D, Liu J, Campbell M, et al. Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL Blood 1993; 82:1257-63.
67. Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of the protein kinases c-Bcr-Abl with proteins of the 14-3-3 family. Science 1994; 266:129-33.
68. Andonou CE, Thien CB, Langdon WY. Tumor induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J 1994; 13:4515-23.
69. Shi Y, Alin K, Goff SP. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev 1995; 9:2583-97.
70. Dai Z, Pendergast AM. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 1995; 9:2569-82.
71. Ploemacher RE, Van Der Sluijs JP, Voerman JSA, et al. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood 1989; 78:2527-33.
72. Sutherland HJ, Lansdorp PM, Henkelman DH, et al. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990; 87:3584-8.
73. Baum CM, Weissman IL, Tsukamoto A.S, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89:2804-8.
74. Petzer AL, Hogge DE, Lansdorp PM, et al. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 1996b; 93:1470-4.
75. Zandstra PW, Conneally E, Petzer AL, et al. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci USA (in press).
76. Lemieux ME, Rebel VI, Lansdorp PM, et al. Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lympho-myeloid differentiation in long-term marrow "switch" cultures. Blood 1995; 86:1339-47.
77. Ploemacher RE, Van de Sluijs JP, Van Beurden CAJ, et al. Use of limiting-diluition type, long-term marrow cultures in frequency analysts of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood 1991, 78:2527-33.
78. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 1996; 8:197-206.
79. Carlo-Stella C, Tabilio A. Stem cells and stem cell transplantation. Haematologica. Haematologica 1996; 81: 573-87.
80. Civin CI, Almeida-Porada G, Lee M, et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88:4102-9.
81. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49:127-67.
82. Eaves C, Udomsakdi C, Cashman J, et al. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma 1993; 11:245-53.
83. Coulombel L, Kalousek DK, Eaves CJ, et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308:1493-8.
84. Udomsakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89:6192-6.
85. Udomsakdi C, Eaves CJ, Lansdorp PM, et al. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 1992; 80:2522-30.
86. Verfaillie CM, Miller WJ, Boylan K, et al. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79:1003-101.
87. Petzer AL, Eaves CJ, Lansdorp PM, et al. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood, 1996a; 88:2162-2171.
88. Petzer AL, Eaves CJ, Barnett MJ, et al. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood (in press).
89. Ichimaru M, Ishimaru T, Mikami M, et al. Incidence of leukemia in a fixed cohort of atomic bomb survivors controls, Hiroshima and Nagasaki October 1950-December 1978. 1981 Radiation Effects Research Foundation, Hiroshima, Japan.
90. Eaves CJ, Eaves AC. Cell culture studies in CML London: Bailliére Tindall & WB Saunders, 1987.
91. Eaves CJ, Eaves AC. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro. Blood Cells 1994; 20:83-95.
92. Strife A, Lambek C, Wisniewski D, et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 1988; 48:1035-41.
93. Bedi A, Zehnbauer BA, Barber J, et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83:2038-44.
94. Maguer-Satta V, Burl S, Liu L, et al. BCR-ABL accelerates C2-ceramide-induced apoptosis. (Submitted).
95. Levin RH, Whang J, Tjio JH, et al. Persistent mitosis of transfused homologous leukocytes in children receiving antileukemic therapy. Science 1963; 142:1305-11.
96. Buckner D, Graw Jr, RG, Eisel RJ, et al. Leukapheresis by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia. Blood 1969; 33:353-69.
97. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis. Blood 1996; 87:1539-48.
98. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068-3076.
99. Haut A, Abbott WS, Wintrobe MM, et al. Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy. Blood 1961; 17:1-19.
100. Kennedy BJ:Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 1972; 29:1052-6.
101. Finney R, McDonald CA, Baikie AG, et al. Chronic granulocytic leukaemia with Ph1-negative cells in bone marrow and a ten year remission after busulphan hypoplasia. Br J Haematol 1972; 23:283-8.
102. Golde DW, Bersch NL, Sparkes RS. Chromosomal mosaicism associated with prolonged remission in chronic myelogenous leukemia. Cancer 1976; 37:1849-52.
103. Brandt L, Mitelman F, Panani A, et al. Extremely long duration of chronic myeloid leukaemia with Ph1-negative and Ph1-positive bone marrow cells. Scand J Haematol 1976; 16:321-5.
104. Mueller L, Hehlmann R. 24 Überlebenszeit bei chronisch myeloischer Leukämie. Klin Wochenschr 1987; 65:673-6.
105. Cunningham I, Gee T, Dowling M, et al. Results of treatment of Ph1-positive chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 1979; 53:375.
106. Corcino J, Krauss S, Waxman S, et al. Release of vitamin B12-binding protein by human leukocytes in vitro. J Clin Invest 1970; 49:2250.
107. Lowenthal RM, Buskard NA, Goldman JM, et al:Intensive leukapheresis as initial therapy for chronic granulocytic leukemia. Blood 1975; 46:835.
108. Lengfelder E, Hehlmann R:Intensive combination chemotherapy in treatment of CML. Bone Marrow Transplant 1995; 17(suppl. 3):355-7.
109. Kantarjian HM, Talpaz M, Kurzrock R, et al. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol 1987;12:322-9.
110. Bolin RW, Robinson WA, Sutherland J, et al. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 1982; 50:1683-6.
111. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia:prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82:398-407.
112. Talpaz M, McCredie KB, Mavligit GM, et al. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62:689-92.
113. Talpaz M. Kantarjian HM, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114:532-8.
114. Niederle N, Kloke O, Doberauer C, et al. Alpha 2-interferon:preliminary treatment results in chronic myeloid leukemia. Dtsch Med Wochenschr 1986; 111:767-72.
115. Kloke O, Niederle N, Qiu JY, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993; 83:399-403.
116. Alimena G, Morra E, Lazzarino M, et al. Interferon alpha-2b as therapy for Ph1-positive chronic myelogenous leukaemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72:642-7.
117. Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia:dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72:350-6.
118. Schofield JR, Robinson WA, Murphy JR, et al.Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121:736-44.
119. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia:effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82:2975-84.
120. Mahon FX, Montastrue M, Faberes C, et al. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-a. Blood 1994; 84:3592-4.
121. Thaler J, Kuhr T, Gasti G, et al. Rekombinantes interferon α-2c bei Ph-positiver chronischer myeloischer leukaemie. Dtsch Med Wochenschr 1991; 116:721-8.
122. Anger B, Porzsolt F, Leichtle R, et al. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989; 58:275-8.
123. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5.
124. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha ni for chronic myeloid leukaemia:improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345:1392-7.
125. Hehlmann R, Heimpel H, Hossfeld DK, et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant 1996; 17 (suppl. 3):S21-S24.
126. Guilhot F, Dreyfus B, Brizard A, et al. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leuk Lymphoma 1991; 4:49-55.
127. Wandl UB, Niederle N, Kranzhoff M, et al. Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia. Int J Cell Cloning 1992; 10:292-298.
128. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122:254-61.
129. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064-77.
130. Hehlmann H, Ansari J. Hasford H, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 1997; 97:76-85.
131. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789-99.
132. Guilhot F, Guerci A, Fiere D, et al. The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside:rational and design of the French trials. Bone Marrow Transplant 1996; 17(suppl.3):181-3.
133. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-16.
134. McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia:results from eight transplant groups. Lancet 1994; 343:1486-8.
135. Kantarjian HM, O'Brien S, Anderlini P, et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87:3069-81.
136. Gratwohl A, Gorin C, Apperley J, et al. The European Group for Blood and Marrow Transplantation (EBMT):a report from the president and the chairman of the working parties. Bone Marrow Transplant. 1996; 18:677-91.
137. McGlave P, Kollman C, Shu XO, et al. The first 1.000 unrelated donor transplants for CML: lessons from the National Marrow Donor Program (NMDP) experience. Proc. 38th Annual Meeting ASH. Blood 1996; 88 Suppl. 1:p. 483a, abstract 1922.
138. Lee SJ, Kuntz KM, Horowitz MM, et al. A decision analysis of unrelated donor transplantation (URD BMT) for CML. Proc. 38th Annual Meeting ASH. Blood 1996; 88 Suppl. 1:p. 484a, abstract 1923.
139. Tura S. Monitoring the effect of allogeneic bone marrow transplantation (BMT) and α-interferon (IFN) in chronic myeloid leukemia. A national prospective study in Italy. Proc. 38th Annual Meeting ASH, Blood 1996; 88 Suppl. 1:p. 682a, abstract 2717.
140. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11:1055-61.
141. Beelen DW, Graeven U, Elmaagacli A, et al. Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85:2981-90.
142. Shepherd P, Richards S, Allan N. Survival after allogeneic bone marrow transplantation (BMT) in patients randomized into a trial of IFN-α versus chemotherapy: no significant adverse effect of prolonged IFN-α administration. Proc. 37th Annual Meeting ASH, Blood 1995:86 (Suppl. 1)p. 94a, abstract 363.
143. Rosti G, Zuffa E, Bandini G, et al. α-interferon for CML patients before allogeneic BMT:any influence on transplant outcome? Proc. 22nd Annual Meeting EBMT, Bone Marrow Transplant. 1996; 17 Suppl. 1, p. 561, abstract 288.
144. Hehlmann R, Ansari H, Hasford J, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 1997; 97: 76-85.
145. Goldman JM, Szydlo R, Horowitz MM ,et al.Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993, 82: 2235-8.
146. Santini V, Zoccolante A, Bosi A, et al. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. Haematologica 1996; 81:201-7.
147. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86:2041-50.
148. van Rhee F, Feng Lin, Cross NJP, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83:3377-83.
149. Craddock C, Szydlo R, Olavarria E, et al. Leukaemia-free survival after allografting for CML: effect of reclassifying donor leukocyte responders as "currently" free of leukemia. Bone Marrow Transplant 1997, 19(suppl. 1):S146 (abstract n. 0581).
150. Spencer A, Brookes PA, Kaminski E, et al. Cytotoxic T-lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Transplantation 1995; 59:1302-8.
151. Speiser DE, Loliger CC, Siren MK, et al. Pretransplant cytotoxic donor T-cell activity specific to patient HLA Class I antigens correlating with mortality after unrelated BMT. Br J Haematol 1996; 93:935-9.
152. Barnado MC, Davey NJ, Bunce M, et al. A correlation between HLA-C matching and donor antireciptent CTL precursor frequency in bone marrow transplantation. Transplantation 1996; 61:1420-3.
153. Devergie A, Madrigal A, Gratwohl A, et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia: impact of HLA-D subtype analysis. Bone Marrow Transplantation (in press).
154. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B and DR identical unrelated donor marrow transplantation. Blood 1995; 86:1606-13.
155. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft versus host disease prophylaxis on engraftment, relapse, and disease free survival in unrelated marrow transplantation for chronic myeloid leukaemia. Blood 1994, 83:1980-7.
156. Hansen JA, Gooley T, Clift R, et al. Unrelated donor marrow transplants for patients with chronic myeloid leukaemia. Blood 1995; 86 (suppl. 1):A479.
157. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84:3948-55.
158. Buckner CD, Stewart P, Clift RA, et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 1978; 6:96-9.
159. Meloni G, De Fabritiis P, Alimena F, et al. Autologous bone marrow transplantation or peripheral blood stem cell transplantation for patients with chronic myelogenous leukemia in chronic phase. Bone Marrow Transplantation 1990; 4(suppl. 4):92-4.
160. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol 1994; 86:76-81.
161. Reiffers J, Cahn JY, Montastruc M, et al. Peripheral blood stem cell transplantation followed by recombinant alpha interferon for chronic myelogenous leukemia in chronic phase: preliminary results. Stem Cells 1993; 11:23-4.
162. Khouri IF, Kantarjian H, Talpaz M, et al. Results with high-dose chemotherapy and unpurged autofogous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 1996; 17:775-9.
163. Mc Glave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous eukemia:results from eight transplant groups. Lancet 1994; 343:1486-8.
164. Reiffers J, Goldman J, Meloni G, et al. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14:407-10.
165. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplant of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML Blood 1994; 83:3068-76.
166. O'Brien SG, Goldman JM. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. J Clin Oncol 1995; 13:541-6.
167. Carlo-Stella C, Mangoni L, Almici C, et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14:425-32.
168. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724-32.
169. Mc Glave PB, Arthur D, Miller WJ, et al. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6:115-20.
170. Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 BCR/ABL gene of the Philadelphia chromosome. Science 1990; 247:824-30.
171. Kirk JA, Reems JA, Roecklein BA, et al. Benign marrow progenitors are enriched in the CD34+/HLA-DRlo population but not the CD34+/CD38lo population of chronic myeloid leukemia: an analysis using interphase fluorescence hybridization. Blood 1995; 86:737-43.
172. Leemhuis T, Leibowitz D, Cox G, et al. Identification of BCR/ABL negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 8:801-7.
173. Carella AM, Gaozza E, Raffo MR, et al. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 5:517-21.
174. Carella AM, Cunningham I, Lerma E, et al. Mobilization and
175. Capria S, Vignetti M, Montefusco E, Cardillo AM, Simone F, Meloni G. Lack of efficacy of a double autograft program to prolong survival of chronic myelogenous leukemia patients in blastic transformation. Haematologica 1996; 81:349-51.
176. de Fabritiis P, Calabretta B. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? Haematologica 1995; 80:295-9.